HHS Public Access

Author manuscript

Nat Neurosci. Author manuscript; available in PMC 2017 August 23.

Published in final edited form as:

Nat Neurosci. 2016 January ; 19(1): 10–19. doi:10.1038/nn.4190.

An Epigenetic Gateway to Brain Tumor Cell Identity

Stephen C. Mack[1], **Christopher G. Hubert**[1], **Tyler E. Miller**[1,2,3], **Michael D. Taylor**[4,5], and **Jeremy N. Rich**[1,6]

[1]Department of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA

[2]Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA

[3]Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA

[4]Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children, Toronto, Ontario, Canada

[5]Division of Neurosurgery, Hospital for Sick Children, Toronto, Ontario, Canada

[6]Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio 44195, USA

Abstract

Precise targeting of genetic lesions alone has been insufficient to extend brain tumor patient survival. Brain cancer cells are diverse in their genetic, metabolic, and microenvironmental compositions, accounting for their phenotypic heterogeneity and disparate responses to therapy. These factors converge at the level of the epigenome, representing a unified node that can be disrupted by pharmacologic inhibition. Aberrant epigenomes define many childhood and adult brain cancers, as demonstrated by widespread changes to DNA methylation patterns, redistribution of histone marks, and disruption of chromatin structure. In this review, we describe the convergence of genetic, metabolic, and micro-environmental factors upon mechanisms of epigenetic deregulation in brain cancer. We discuss how aberrant epigenetic pathways identified in brain tumors affect cell identity, cell state, and neoplastic transformation, in addition to the potential to exploit these alterations as novel therapeutic strategies for the treatment of brain cancer.

INTRODUCTION

Brain tumors encompass a wide spectrum of over 120 histologically, demographically, clinically and molecularly distinct diseases[1], and are one of the most common causes of

Corresponding author: Jeremy N. Rich, MD, MHSc, Department of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA. Telephone: (216) 636-0790; Facsimile: (216) 636-5454; drjeremyrich@gmail.com.

Conflict of Interest

The authors declare no conflict of interest.

cancer-related death in children and adults. Genome-sequencing studies have uncovered the landscape of genetic alterations present in many pediatric and adult cancer types[2], and highlights a convergence on deregulated epigenomes in the form of aberrant DNA methylation signatures, histone modification patterns, and disorganized chromatin architecture[3–7]. In adult glioblastoma (GBM, World Health Organization grade IV glioma), the most aggressive and prevalent adult primary intrinsic brain cancer, nearly 46% of patients harbor at least one mutation of an epigenetic regulator amidst a diversity of oncogenic pathway mutations[8]. Equally striking is the pediatric counterpart of glioblastoma where one highly prevalent mutation occurs in a histone protein[9]. Somatic mutations and structural variations that target regulators of epigenetic modifications and functional regulatory elements have been reported across several aggressive pediatric and adult brain cancers such as glioblastoma [5, 8–10], medulloblastoma [6, 11–18], ependymoma[19], atypical teratoid rhabdoid tumors (ATRT)[20, 21], diffuse intrinsic pontine gliomas (DIPG) [22–27], and embryonal tumors with multilayered rosettes (ETMR) [28]. The function of these epigenetic alterations is likely context dependent, but ultimately influences cell identity and cell state transitions during neoplastic transformation (Figure 1). Brain cancer cells are not only heterogeneous in their genetic composition, but also reside in varying microenvironments and interact with different cell types. Therefore, factors such as altered cellular metabolism and the microenvironment may critically define the neoplastic effects of epigenetic programs in the process of brain tumor development[7, 29–41]. In this review, we will detail the collective genetic, metabolic, and microenvironmental alterations present during brain tumorigenesis, and discuss the impact these changes have upon epigenetic programs important for cell state transition or maintenance. Further, we will highlight the therapeutic potential of targeting brain tumor cell state by modulation of epigenetic signatures.

The Epigenetic Gateway to Cell Identity and Neoplastic Transformation

Cancer cells are characterized by a state of uncontrolled proliferation and replicative immortality[42]. The epigenetic landscape defines cell state, supporting epigenetic control as an essential node of transformation. It is now clear based on Nobel prize-winning work of Shinya Yamanaka[43] and many others, that the state of a cell is dynamic and more plastic than previously thought. Various studies demonstrating direct cell conversion to specific lineages, including multiple types of neural progenitors that are the putative cell of origin of many brain tumors highlight the ability of cells to transform their state with the introduction of only a few transcription factors[44–46]. Cancer cells capitalize on this cellular plasticity to acquire developmental programs that endow upon the cell limitless self-renewal capacity, similar to that of reprogrammed induced pluripotent stem cells (iPSCs) and neural stem cells. In fact, there are close parallels between cellular reprogramming and oncogenic transformation. Yamanaka transcription factors, including SOX2 and MYC [47–49], and many of the epigenetic modifier genes that are necessary for cellular reprogramming have an oncogenic role in cancer (reviewed in [50]). Suva et al. demonstrated, similar to direct conversion of non-transformed cells that they could reprogram a differentiated cancer cell into a tumor-propagating cell (i.e. satisfying a key functional criterion for glioma brain tumor stem cells (BTSCs)) with four master transcription factors (POU3F2, SOX2, SALL2 and OLIG2)[48]. Restoring, at least in part, the epigenome of a native BTSC was necessary to regain tumorigenic potential, supporting the concept that epigenomic programs define the

cancer cell state. Resetting the epigenetic landscape of BTSCs using a method similar to iPSC reprogramming, and given external cues to set up an epigenetic program distinct from brain tissue attenuates tumor formation[51, 52]. While these studies and others demonstrate in a laboratory setting that epigenetic regulation can drive or inhibit cancer growth, human tumors are not formed from the exogenous introduction of transcription factors. Tumors, in particular brain tumors, are heterogeneous at the single cell level and organized in a hierarchical structure composed of cells with varying cell states[53, 54]. Genetic alterations, signaling alterations, metabolic alterations and microenvironmental conditions converge to dictate the epigenetic landscape of individual cells (Figure 1). This landscape, in turn, defines cell state and influences cell signaling, metabolism, the microenvironment and even the genetic landscape[15, 55–58]. Molecular alterations within cancer cells promote cancer growth, but multiple deregulated pathways may converge to create an oncologic epigenome: the altered epigenome may lock cells in a stem-like state, inhibiting normal differentiation[19, 53, 59–61]. In concert, tumor epigenomes inhibit tumor suppressor gene expression, drive oncogenic activation, and further render the cell of origin susceptible to neoplastic transformation[2, 55–57, 62].

Convergence on Chromatin Architecture

Characterization of histone modifications and their role in normal cellular function has provided insight into the potential mechanisms of epigenetic de-regulation in brain cancer[63, 64]. Octamers of histone proteins are responsible for wrapping 147 base pair units of double-stranded DNA into compacted subunits called nucleosomes. Post-translational modification of histones by methylation, acetylation, phosphorylation, sumoylation, and ubiquitylation etc., instruct states of euchromatin and heterochromatin (As reviewed in [65]). Histone modifications further define distinct regions of the epigenome such as enhancers, promoters, and gene bodies (Figure 2). Modifications of histone amino acid residues are mediated by enzymes (‘epigenetic writers’), such as histone methyltransferases (i.e. Enhancer of Zeste Homolog 2, EZH2) and acetyltransferases (i.e. P300/CREB-binding protein, CBP), which catalyze the addition of methyl or acetyl groups, and histone demethylases (i.e. Jumonji Domain Containing 3, JMJD3) and deacetylases (i.e. histone deacetylases, HDACs), which facilitate their removal (‘epigenetic erasers’). Proteins that recognize histone modifications, known as histone ‘readers’, recruit additional proteins and protein complexes that facilitate transcriptional regulation. The organization of larger-scale chromatin structure is regulated by chromatin remodelers and chromatin associated proteins. In brain cancer, mutations have been identified at nearly all levels of chromatin regulation from mutations of histones, to enzymes that catalyze histone modification, to proteins that facilitate larger-order chromatin structure (Figure 2).

Childhood Tumors Highlight Epigenetic Dependencies in Brain Cancer

An emerging theme in brain cancer sequencing studies is the relative decreased prevalence of mutations observed in childhood versus adult brain tumors[5, 6, 8, 16, 17, 19, 20, 66–71]. This holds true for other pediatric cancers such as infant leukemia, neuroblastoma, and retinoblastoma, which exhibit lower mutation rates as compared to highly mutated adult tumors, such as melanoma and lung cancer[17, 19, 66–68, 70, 71]. Of the few recurrent mutations identified in brain cancer genomes, many target chromatin associated proteins or histone

proteins themselves, termed ‘landscaping genes’, due to their potential widespread effects on transcriptional programs[4–9, 12, 13, 15, 17, 19, 28, 69]. ATRTs harbor remarkably silent genomes, yet exhibit recurrent mutations or deletions of the *SMARCB1* gene (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily B) [20, 21, 72] (Figure 2). *SMARCB1* encodes a subunit of the SWI/SNF chromatin-remodeling complex, which functions as a tumor suppressor protein that is highly mutated in several cancers[73]. Homozygous deletion of *SMARCB1* in mice leads to embryonic lethality, while heterozygous loss leads to aggressive tumors that recapitulate human rhabdoid tumors[74–76]. It is important to note that *SMARCB1* loss is deleterious to a vast majority of cells, and mutation within an exclusive cellular and developmental context leads to neoplastic transformation[77]. As shown in Drosophila neuroblasts, proper lineage specification by the SWI/SNF component Osa (ARID1) prevents tumorigenesis, by restricting self-renewal and inhibiting de-differentiation[78]. Two groups recently described the genetic landscape of another aggressive pediatric brain tumor, ependymoma, in which hindbrain tumors exhibit no recurrent mutations in coding space and no evidence of recurrent gene fusions or focal somatic copy number alterations[19, 79, 80]. This was in contrast to its direct adult ependymoma counterpart, which harbored widespread genomic instability[81]. The DNA methylome of infant hindbrain ependymoma displays aberrant DNA hypermethylation at CpG islands, described as a CpG Island Methylator Phenotype (CIMP). Importantly, hypermethylated genes converged upon embryonic stem cell (ESC) targets regulated by the Polycomb Repressor Complex 2 (PRC2), suggesting that epigenomic alterations could be disrupting cell state and differentiation programs important to ependymoma development. A link between ESC programs and cancer is further demonstrated in the embryonal brain tumor ETMR, which harbors a fusion between a highly amplified microRNA cluster (C19MC) and *TTYH1* (Tweety family member 1)[28, 82, 83]. A downstream consequence of the fusion is aberrant overexpression of a novel DNA methyltransferase 3B (*DNMT3B*) isoform normally and exclusively expressed in the first weeks of neural tube development. Observations in ATRT, ependymoma, and ETMR, alongside several other cancers, suggest that neoplastic transformation is a process dependent on proper maintenance of stem cell programs through tight chromatin regulation. While these aberrant epigenetic events have been observed through genome-wide approaches, future validation will be needed to model these alterations during the initiation and progression processes of brain tumorigenesis.

Mutations of Histone Proteins

Recurrent genetic lesions linking epigenomic programs to brain tumor formation is perhaps best exemplified in pediatric glioblastoma and DIPG, which harbor frequent mutation of *H3F3A,* encoding the H3.3 histone variant, and to a lesser extent *HISTH1B* and *HISTH1C*, encoding the H3.1 variant[9, 22, 23, 26, 84–87]. These mutations target the histone H3 lysine 27th position (K27M), a direct site important for epigenetic post-translational modifications, and the neighboring residue G34R or G34V, which is thought to affect a nearby lysine residue at the 36th position (H3K36)[10] (Figure 2). The H3.3 K27M mutation affects a site of post-translational modification and is associated with global decreased K27 methylation and increased K27 acetylation[88]. Further, the K27M mutant results in aberrant redistribution of residual patterns of H3K27me3 within the tumor epigenome[85, 86]. ESC-derived neural precursor cells (NPCs) can be transformed with a combination of H3.3-K27M over-

expression, shRNA knockdown of TP53, and over-expression of PDGFRA (platelet-derived growth factor receptor A)[89]. Importantly, ESCs and terminally differentiated cells are resistant to transformation, suggesting that the effect of the K27M mutation is highly restricted to a cell type occurring within a defined NPC population during embryonic development. The temporally and anatomically distinct tumors defined by K27M and G34R/V mutations, suggest unique cells of origin and/or cell states that are required for tumor initiation[87]. Mutations have also been reported in the proteins that facilitate histone H3.3 incorporation, such as alpha thalassemia/mental retardation syndrome X-linked (ATRX) and death-domain associated protein (DAXX)[9, 90]. The significance and functional characterization of these mutations in the setting of epigenomic reprogramming remains an area of active and future investigation.

Mutations of Histone Modifiers

Enzymes that catalyze the addition or removal of modifications are recurrently mutated, amplified, or deleted in brain cancer genomes. These include *MLL2* and *MLL3* (mixed-lineage leukemia 2/3 in medulloblastoma and adult glioblastoma)[6, 16, 17, 69], *SMARCB1* (ATRT)[20, 21], *SMARCA4* (glioblastoma, medulloblastoma, ATRT)[5, 8, 9, 14, 16, 17, 69, 87, 91], and *SETD2* (SET domain containing 2 in both pediatric and adult glioblastoma)[91] mutations occurring in a diverse set of adult and pediatric brain tumors (Figure 2). Whole-exome and whole-genome sequencing studies of medulloblastoma have revealed the most commonly mutated chromatin modifier to be *MLL2,* which mediates histone H3 lysine 4 (H3K4me3) tri-methylation, a mark of active transcription[6, 11, 14, 16, 17]. Further, the histone lysine 27 demethylase, *KDM6A,* is recurrently mutated, and associated with increased H3K27me3 levels in a group of medulloblastomas with a poor prognosis (Group 4), which also overexpress EZH2. Poor prognosis medulloblastomas (Groups 3 and 4, which are not driven by sonic hedgehog and wnt signaling) also harbor subgroup-associated mutations in *CHD7* (chromodomain helicase DNA binding protein 7) and *ZMYM3* (zinc finger, MYM-type 3), which converge on regulation of gene expression by H3K4me3. Given the role of H3K27me3 in repressing lineage specific genes in stem cells, it is hypothesized that Group 3 and 4 medulloblastomas retain stem-like signatures through accumulation of H3K27me3 and abrogation of H3K4me3 mediated transcription. Interestingly, these alterations are in contrast to the global loss of H3K27me3 levels in pediatric glioblastoma, and perhaps suggest that perturbation of a global balance and/or distribution of H3K27me3 and H3K4me3 patterns may reflect cell state specific dependencies in neoplastic transformation. A major effort moving forward will be functional characterization of these epigenetic alterations and identification of specific developmental cell types where their epigenetic deregulation promotes tumor formation.

Genomic Regulatory Elements of Brain Tumors

The convergence on histone modifications and chromatin regulation highlights the importance of understanding and mapping these modifications in brain tumors. In tumors, such as pediatric glioblastoma and ependymoma, histone modification mapping by chromatin immunoprecipitation followed by high density sequencing (ChIP-seq) has demonstrated aberrant epigenetic patterns of histone H3K27 tri-methylation[10, 19, 85]. The linkage between epigenetic modifications and cell identity and lineage specification

underscores the importance of understanding the epigenetic landscape in brain cancer. Recent studies have highlighted the importance of clusters of enhancer elements, termed 'Super-Enhancers', which both identify and regulate genes involved in cell identity and disease[92] (Figure 2). These epigenomic features can be co-opted in cancer by mutations and structural variations[93]. In Group 3 medulloblastoma, Super-Enhancers are hijacked by structural variations, which lead to aberrant activation of *GFI1* and *GFI1b* (growth factor independent 1 transcription repressor) oncogenes[12]. In several brain tumors, non-coding mutations have been observed in the promoter regions of *TERT* (telomerase reverse transcriptase, which encodes the catalytic subunit of the enzyme telomerase), which are enriched in tumors characterized by low-rates of self-renewal[94, 95]. The consequence of these mutations in glioblastoma is the aberrant recruitment of the GABP (GA Binding Protein) transcription factor[96]. Future in depth sequencing of non-coding regions and integration with histone modification and transcription factor maps may uncover crucial genes that maintain cell state and the factors that govern their expression.

Altered DNA Methylation Patterns in Brain Cancer

Changes in DNA methylation patterns have been widely reported in cancer in the form of DNA hyper-methylation and silencing of tumor suppressor genes, and loss of methylation of oncogenes and repetitive elements[97]. To date, genome-wide studies focusing largely on promoter regions and CpG islands, have revealed novel mechanisms of oncogenic and tumor suppressor gene regulation in cancer. Examples include widespread accumulation of DNA methylation in *IDH1* (Isocitrate dehydrogenase 1) mutated gliomas (see metabolism section below)[39, 98], and the establishment of CIMP phenotypes in other tumors, such as ependymoma (Figure 2). Further, an important application of DNA methylation profiling is to identify signatures associated with genetic lesions, and the use of DNA methylation as a method for robust molecular stratification[8, 19, 21, 87]. It is also posited that DNA methylation patterns may reflect the specific cellular states and/or cells of origin present during transformation. Advances in our understanding of the epigenomic landscapes of normal human and murine neural stem cells and cellular hierarchies may shed light upon the potential cell identity and cell state transitions that occur in the early stages of brain tumor initiation. Technological advances have also allowed for genome-wide characterization of brain tumor DNA methylomes using whole-genome bisulfite sequencing (WGBS). Early WGBS studies have revealed novel mechanisms of transcriptional regulation in medulloblastoma and ependymoma, and have provided an integrated view of DNA methylation and histone modification landscapes in brain tumors[15, 19].

Epigenetic Perturbation of Genetic Landscapes

In addition to influences on cell state, epigenetic alterations have been shown to have widespread effects on the genetic landscape of tumor cells. For example, methylated cytosine bases are highly prone to mutation by spontaneous deamination to thymine, thus creating opportunities for deregulation of tumor suppressor genes and oncogenes in the absence of intact DNA repair mechanisms[99]. Furthermore, it has been shown that hypomethylation of transposable elements have been observed widely in cancer, and may contribute significantly to genomic instability through aberrant translocation of DNA sequences[100]. At the chromatin level a direct association between histone modifications and

genetic alteration is evidenced in tumors that overexpress the H3K9/36me3 lysine demethylase KDM4A/JMJD2A, which leads to regional DNA copy gain in the absence of global chromosomal instability[58]. This illustrates a scenario in which aberrant chromatin modulator expression could establish somatic copy number changes during neoplastic transformation[58]. From cancer genome sequencing studies, evidence is emerging that links regional mutation density with the degree of heterochromatin as marked by H3K9me3[56]. These findings demonstrate that somatic mutations are not distributed uniformly across the human genome, and are associated with epigenomic topographies derived from the most likely cell type of origin and cell state during malignant transformation[55].

Cellular Microenvironment Influences Epigenetic State of Brain Tumor Cells

Brain tumor cells do not exist in isolation, but are part of a dynamic and spatially distributed system, interacting with a wide-diversity of environments and cell types. For example, active neuronal activity promotes mitosis of the putative cells of origin in high-grade glioma through NLGN3 (Neuroligin 3) secretion[101]. Brain tumor stem cells (BTSCs), in particular, exhibit a complex relationship with their microenvironment: they can actively modify and shape their own environment but are also regulated, supported, and directed by microenvironmental signals (Figure 3). This intricate crosstalk is crucial to maintain a stem cell state and occurs within a localized, supportive microenvironment around the stem cells called a niche. There are a multitude of factors within the stem cell niche that affect the cellular state of brain tumor cells including nutrient availability, hypoxia, pH, and cell-cell interactions. In other systems, stem cell state maintenance and cell state change or differentiation are governed epigenetically.[102] So far little is known at the mechanistic level as to how niche cues regulate brain tumor epigenetics. However, a number of studies have revealed how external environmental cues functionally change brain tumor cell state through unexplored epigenetic mechanisms.

The Hypoxic Niche—Areas of hypoxia and necrosis can be a diagnostic feature of many malignant tumors, including glioblastoma. Historically, this has been hypothesized as the expected occurrence when a tumor's growth outpaces its blood supply, leaving behind starved and/or dying cells, but recent studies have revealed that micro- and macro- cellular relationships within a tumor's hypoxic niche are far more complex. Many normal adult stem cell niches as well many steps of embryonic development are naturally hypoxic.[103] Hypoxic niche support of stem cells may be a conserved feature of development, normal tissue maintenance, and cancer. Although cells in nutrient-rich environments have the resources to facilitate rapid proliferation and tumor growth, it may be the cells within the hypoxic niche that actually drive tumor progression and recurrence due to the stem-like transcriptional and epigenetic adaptations they undergo in this environment (Figure 3).

The direct molecular responses of brain tumor cells to hypoxia are principally mediated by the hypoxia-inducible factor (HIF) family of transcription factors, especially HIF1α and HIF2α.[104] In glioblastoma biopsies, BTSCs are enriched in peri-necrotic regions in the context of HIF activation.[105] A number of studies have demonstrated that hypoxia directly mediates expansion of the BTSC pool and that this is dependent on HIF1 and HIF2. [31, 106] However, whereas HIF1α appears generally necessary for glioma survival in hypoxia,

HIF2α is specifically necessary to sustain BTSC.[31] This may be mediated through HIF2 enhancement of MYC transcriptional activity[30] that is required for BTSC maintenance and proliferation.[107]

Little is known about the direct epigenetic consequences of hypoxia and HIF activation in brain cancer, but exploration of this field is beginning. In NPCs of the developing brain, HIF1α interacts with Notch signaling and can affect cell fate decisions through epigenetic alteration.[41] In glioblastoma, the histone methyltransferase mixed-lineage leukemia 1 (MLL1) is induced by hypoxia; and loss of MLL1 reduces the expression of HIF transcripts and HIF2α protein,[108] indicating a potential feedback loop sustaining hypoxic response. Depletion of MLL1 inhibited the expression of HIF2α and target genes, including vascular endothelial growth factor (VEGF), and reduced BTSC self-renewal, growth, and tumorigenicity.[108]

In other cancers, HIF-independent hypoxia mediated epigenetic silencing of tumor suppressor genes has been described. Specifically, the *BRCA1* and *RAD51* promoters have been shown to be repressed by local chromatin restructuring via H3K4 demethylation, H3K9 methylation, and H3K9 deacetylation[109]. It is important to note that a growing number of epigenetic modifiers, which are deregulated in numerous cancer types, are dependent upon proper oxygen maintenance (see metabolism section below). As one example, various cancer cell lines grown *in vitro* versus the hypoxic conditions they experience in an *in vivo* xenograft setting, result in a global induction of DNA hypomethylation[110].

For a wide variety of cancers, extracellular solid tumor pH has been determined to be significantly more acidic than in normal tissues[111] Tumor hypoxia in particular can induce a metabolic shift that causes acidosis,[112] although these two microenvironmental components can also occur independently.[32] Importantly, acidic conditions promote the expression of BTSC markers, self-renewal and tumor growth through augmentation of HIF2 transcriptional responses.[35] In response to an acidic environment, and decreasing intracellular pH (pH(i)), cancer cells have been shown to respond and attempt to regulate pH(i), by global de-acetylation, which is accompanied by extensive redistribution of acetylation across the genome[113]. This suggests that exposure to low pH, either derived extrinsically from the niche or created autonomously by cellular alteration of the niche, promotes malignancy through the induction of distinct cellular phenotypes (i.e. BTSC), and is a process tightly associated with epigenetic alterations.

The Perivascular Niche—A hallmark of glioblastoma is the development of histologic regions of microvascular proliferation, often displaying highly disorganized angiogenic vessels and overall high vascularity (Figure 3). Angiogenesis is essential for tumor survival and is the canonical downstream effect of HIF transcriptional activity. Medulloblastoma cells and BTSCs both consistently secrete elevated VEGF levels[40, 114]. This effect is markedly enhanced by hypoxia and serves to increase endothelial migration, motility and vasculogenesis[114]. This suggests initial epigenetic state changes within endothelial cells as BTSCs recruit blood vessels through VEGF secretion, followed by epigenetic adaptation of the BTSCs as they adopt a new cell state to complement their changing niche. The regions around these blood vessels are high in oxygen and nutrients and harbor an increased number

of stem cells[115]. Cells within glioblastoma, medulloblastoma, ependymoma and oligodendroglioma are located in close proximity to tumor capillaries. Within this perivascular niche, soluble factors released from the endothelial cells can promote self-renewal and proliferation of BTSCs[29]. In medulloblastoma, perivascular stem cells are resistant to radiation and likely give rise to tumor recurrence,[116] echoing similar findings in glioblastoma[117].

Infiltration and enrichment of tumor-associated macrophages (TAMs) is a common feature of glioblastoma, where TAMs are preferentially located in the perivascular niche (Figure 3)[118]. Their mutual enrichment and proximity has suggested a relationship between TAMs and BTSCs. Although activated M2 TAMs have well known pro-tumor effects[119] including in glioma,[120] the mechanisms of the potential BTSC-TAM relationship have been largely undefined. Recently, Zhou et al. al. demonstrated that BTSCs preferentially secrete the cytokine periostin (POSTN), which attracts TAMs. POSTN repression resulted in a striking reduction in TAM density, inhibition of tumor growth, and improved survival of tumor-bearing mice[121]. TAMs or microglia in the glioblastoma microenvironment may also play a significant role in TGFβ and NF-κB–dependent mesenchymal differentiation, enabling glioblastoma cells to switch subtypes to a more radio-resistant cell state.[122] This may further be governed through aberrant activation of the STAT3 (Signal transducer and activator of transcription 3) pathway in glioma by frequent loss or repression of the tumor-suppressor phosphatase PTPRD (protein tyrosine phosphatase, receptor type, D)[123]. For these state-change events to be lasting and maintained by the niche, BTSCs must adopt a stem-like chromatin state.

Epigenetic regulation of tumors by endothelial cell signals—Beyond being a good place for a stem cell to grow due to the abundance of oxygen, nutrients, and growth factors, cells of the perivascular niche directly interact and bidirectionally communicate with brain tumor stem cells (Figure 3). The molecular mechanisms through which the perivascular niche controls brain tumor stem cell state are beginning to be discovered. BTSCs express Notch receptors while endothelial cells of the niche express Notch-activating ligands[124]. Whereas co-xenograft of brain tumor cells and endothelial cells increases tumor initiation and growth, knockdown of Notch ligands in the co-injected endothelial cells reduces tumor growth[29, 124]. BTSCs in the hypoxic niche secrete VEGF,[114] which in turn can both recruit new blood vessel formation and stimulate endothelial cells to secrete Notch ligand,[125] which can then stimulate Notch signaling in BTSCs. This feed-forward loop may be yet another example of microenvironmental modification initiated by BTSCs to promote maintenance of their own cell state.

Cancer cell dormancy is a potential mechanism to explain many detrimental clinical findings including resistance to chemotherapy, tumor recurrence, and metastasis.[126] Entry and exit from cancer dormancy is mediated by epigenetic alterations, signaling pathways, and transcriptional circuits that are also known to drive stem cell reprogramming and maintenance[126]. The key coagulation mediator Tissue Factor (F3) expressed by vascular endothelial cells and is linked with malignant breast cancer[127], where protein secretion by endothelial cells during neovascularization my trigger an exit from dormancy and cancer proliferation.[128] In glioma, cancer cell dormancy may be governed by F3. F3 activity

enabled glioma cells to form a microenvironment containing angiogenic and inflammatory cells. Strikingly, glioma cells lacking F3 remain viable but dormant unless they are supplemented with exogenous F3.[129] This work suggests that microenvironmental changes triggering exit from dormancy are accompanied by more permanent epigenetic, genetic, and phenotypic changes in the glioma cells resulting in tumorigenesis.

Influences from the microenvironment can affect, promote, preserve, and even dictate brain tumor cell states. These findings could have vast clinical implications and suggest therapeutic targets greatly needed in this disease. However, we currently lack the basic mechanistic understandings of how these phenotypic changes in brain tumor cell states are affected and maintained at the chromatin level. Advancing technologies that allow epigenetic analysis at high fidelity with lower numbers of cells may enable such studies to be performed in the near future.

Cellular Metabolism Influences Brain Cancer Epigenetic State

The metabolic state of brain tumor cells is highly influenced by alterations in tumor microenvironment, and linked directly to changes in global epigenetic patterns (Figure 4). Microenvironmental alterations dictate fuel sources available to brain tumor cells, such as glucose[130, 131], acetate[33, 132] and glutamine[133], which limit or alter the distribution of substrates required for post-translational epigenetic modifications[33, 132]. Mutations of metabolic pathways have been observed in several cancers, in addition to brain tumors, as a means of disrupting epigenetic and cellular state[134, 135]. In glioma, one of the most common recurrent mutations occurs in *IDH1*, resulting in the accumulation of an oncometabolite (R-2-hydroxyglutarate, R-2-HG), which functions to inhibit the activity of multiple α-ketoglutarate (α-KG) dependent dixoygenases. Through competitive inhibition, R-2-HG impairs the activity a wide-variety of histone and DNA demethylases such as the Jmjc domain-containing histone demethylases (KDMs), RNA demethylases, and the TET (ten-eleven translocation) family of DNA hydroxylases that facilitate DNA de-methylation. (Figure 4). These enzymes comprise a family of 2-oxoglutarate-dependent dioxygenases that depend upon iron and oxygen for their function, further linking, metabolic and hypoxic regulation with epigenetic programs. However, these widespread effects also increase the difficulty of deciphering the functional consequence(s) of the IDH mutations, specifically whether some of these effects are a mere product of increased R-2-HG production. One of several consequences from IDH mutations is aberrant methylation of histones at several lysine residues, and acquisition of a CpG island methylator phenotype through DNA hypermethylation[37–39, 98]. While the function of *IDH1* mutations in glioblastoma remains to be fully characterized, the result of increased histone methylation prevents lineage-specific progenitors from differentiating into terminally differentiated cells[38]. Furthermore, chemical inhibition of IDH1 has been shown to promote glioma differentiation[136]. Like pediatric glioblastomas, which harbor K27M mutations, the convergence on epigenetic programs elicited by metabolic state changes, suggests that these types of mutations may function to activate a stem- or progenitor- cell states required for tumorigenesis.

Like all cancers, brain cancers display the Warburg effect, a preferential utilization of aerobic glycolysis for energy supplies and macromolecule synthesis. This is especially true

within the hypoxic niche where both oxygen and nutrients supplied by distant blood vessels are scarce (Figure 3). One method utilized by BTSCs to meet their metabolic needs is to co-opt expression of the high affinity glucose transported, GLUT3, to efficiently scavenge glucose from their environment [137]. (Figures 3 and 4) More strikingly, non-stem glioblastoma cells grown in restricted glucose exhibited increased levels of the ESC master transcription factors and showed significant functional enrichment for stem-like cells, indicating adaptation and reprogramming to a more stem-like state [137]. The exact epigenetic mechanisms underlying these adaptations are so far unknown. However, the genomic locus of GLUT3 is part of a conserved, 200-kb gene cluster that is highly enriched for genes associated with pluripotency, including the master ESC transcription factor NANOG [138]. This region is under control of another the master ESC transcription factor, OCT4 (Octamer-binding transcription factor 4) [139]. It is possible that cancer cells can gain GLUT3 expression and stem cell properties simultaneously by epigenetically de-repressing this region of chromatin during stem cell reprogramming.

Another mechanism utilized by brain tumors and brain metastases to meet tumor metabolic demands is the utilization of acetate by the enzyme ACSS2 (Acetyl-coenzyme A synthetase, cytoplasmic).[33, 132] Acetate and co-enzyme A are oxidized by ACSS2 to form the central metabolite Acetyl-CoA necessary for a wide variety of cellular processes including epigenetic modulation through histone acetylation.[140] Histone acetylation has a very short half-life in tumor cells creating an abundant supply of intracellular acetate to be utilized by ACSS2,[33] and also necessitating a continued active upkeep of histone modifications to maintain cell state. Indeed, acetate is utilized by ACSS2 in both brain tumor models and in brain tumor patients and its expression correlates with tumor aggressiveness in a variety of cancers including brain tumors.[132]

Brain Tumor Therapy by Disrupting Epigenetic Regulators of Cell State

The convergence of genetic, metabolic, and microenvironmental alterations on cell state, and the dependence of cell state on epigenomic programs, suggests that targeting epigenetic mechanisms could be a valuable strategy for treatment of brain tumors. Numerous preclinical studies have shown that brain tumors are sensitive to a variety of inhibitors of epigenetic modifications, several of which are FDA approved (Figure 2)[141–143]. These include DNA methylation and HDAC inhibitors, such as decitabine and vorinostat, respectively. Targeted epigenetic modulation has already shown promise in numerous pre-clinical models of brain tumors characterized by aberrant epigenetic programs. In the case of DIPGs that harbor the H3.3 K27M mutant, and global loss of H3K27 tri-methylation, a H3K27 demethylase (JMJD3) inhibitor (GSK-J4) has been shown to be effective for reducing tumor growth by elevating H3K27 tri-methylation[144]. Furthermore, GSK-J4 exhibits synergistic activity with the HDAC inhibitor, pabinostat[145]. In brain tumors such as glioblastoma, ATRT and ependymoma, characterized by aberrant H3K27me3 patterns, highly specific EZH2 inhibitors (i.e. GSK343) have been shown to be effective at restricting tumor growth in pre-clinical models[19, 146, 147]. A novel avenue of targeting histone modification is inhibiting the readers of acetylation (i.e. BRD4, bromodomain containing 4), which mark active enhancers and super-enhancers, using inhibitors of bromodomain containing proteins, such as JQ1[148]. JQ1 treatment has been shown to be effective in both

MYC and SHH (sonic hedgehog)-driven medulloblastoma by targeting cancer dependency genes driven by super-enhancers[149, 150]. This represents a collection of early studies examining an emerging concept of reversing epigenetic signatures in brain tumors using novel small molecule epigenetic inhibitors. Understanding the function and potential requirements of specific epigenetic marks in brain tumors, alongside development of specific epigenetic drugs, may reveal new opportunities for rationale and targeted therapeutics. Targeting cellular state through manipulation of epigenetic regulators represents an alternative or complementary approach to 'drugging' specific genetic lesions.

Moving Forward

Genomic sequencing of several types of brain tumors -- astrocytomas, oligodendrogliomas, medulloblastomas, ependymomas, meningiomas, ATRT -- have yielded remarkably granular genomic landscapes. Glioblastoma and other brain tumors harbor mutations that are infrequent in isolation but disrupt normal function of a limited cohort of pathways (p53, retinoblastoma, receptor tyrosine kinase signaling, and chromatin-associated molecules). Sadly, this avalanche of information has made relatively modest impact on the clinical practice of neuro-oncology. Therapeutic trials against driving genetic abnormalities amenable to therapeutic targeting – like EGFR – have been largely negative in most brain cancers. Standard-of-care for most brain tumors remains focused on maximal surgical resection, radiotherapy, and chemotherapy. Indirect targeting of the tumor through anti-angiogenics (e.g. bevacizumab) and immunotherapies (vaccines, adoptive therapies, immune checkpoint inhibitors, and oncolytic viruses) have demonstrated preclinical activity but mixed efficacy in clinical trials. The convergence of genomic alterations, microenvironmental conditions, and metabolic reprogramming to create an epigenetic landscape that promotes aberrant activation and maintenance of stem cell-like transcriptional programs may offer a coherent strategy to improve diagnosis, prediction of prognosis, and therapies. Global chromatin reprogramming may be detectable at the earliest stage of transformation empowering early detection and prognosis. Circulating DNA and tumor cells have proven informative of tumor development and progression, suggesting that simultaneous assessment of tumor genetics and epigenetics may better inform the status of tumors. Currently unclear is the landscape, prevalence and importance of non-coding mutations and structural variations, which will be revealed as future brain tumor whole-genomes are sequenced to greater depth. Delineating the functional consequences of non-coding alterations will benefit from comprehensive and integrated mapping of histone modifications and chromatin structure in brain tumors. Epigenomic mapping, such as enhancer profiles, may also reveal the master transcription factors important for maintaining cancer cell state in addition to the mechanisms that lead to oncogenic transformation. The multiple influences upon epigenetic mechanisms including both intrinsic factors (i.e. mutations) and extrinsic factors (i.e. microenvironment) may complicate epigenomic mapping of brain tumors. However, identifying pathways of convergence and dependencies on epigenetic programs may reveal important insights into the molecular biology of brain tumors, and new avenues for cell state therapies. While targeting epigenetic regulators in tumor cells – e.g. inhibitors of IDH1 or BRD4 – may offer benefit, sustained tumor control will be most likely achieved with combinatorial targeting strategies with conventional or targeted therapies. Potentially, inhibitors of chromatin-associated proteins could induce

synthetic lethality with other treatments, disrupt the growth of heterogeneous tumor populations, and attenuate mechanisms of progression. Transforming neuro-oncology care will require more complex modeling of tumor biology through the integration of epigenetics and the multi-dimensional interactions with genetics, metabolism, and the microenvironment. Caution must be exercised as each new advance in oncology has been hailed as a potential cure, but reprogramming tumor cells towards a differentiated phenotype could reverse therapeutic resistance, immune escape, invasion, and angiogenesis.

Acknowledgments

We sincerely apologize to those investigators whose work we were unable to cite due to space limitations. We thank David Schumick (Center of Medical Art and Photography, Cleveland Clinic) for assistance with figure preparation. This work was supported by The Banting Fellowship (SCM),, James S. McDonnell Foundation (JNR) and NIH grants: F32 CA189647 (CGH), F30 CA183510 (TEM), T32 GM007250 MSTP (TEM),, CA154130 (JNR), R01 CA169117 (JNR), R01 CA171652 (JNR), R01 NS087913 (JNR), R01 NS089272 (JNR). MDT is supported by a CIHR Clinician Scientist Phase II award, funds from the Garron Family Chair in Childhood Cancer Research at The Hospital for Sick Children and The University of Toronto, and operating funds from the Canadian Institutes of Health Research, the National Institutes of Health (R01CA159859 and R01CA148699) and the Pediatric Brain Tumor Foundation.

References

1. Louis DN, et al. The 2007 WHO classification of tumours of the central nervous system. Acta neuropathologica. 2007; 114:97–109. [PubMed: 17618441]
2. Lawrence MS, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014; 505:495–501. [PubMed: 24390350]
3. Bettegowda C, et al. Exomic sequencing of four rare central nervous system tumor types. Oncotarget. 2013; 4:572–583. [PubMed: 23592488]
4. Jiao Y, et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget. 2012; 3:709–722. [PubMed: 22869205]
5. Parsons DW, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321:1807–1812. [PubMed: 18772396]
6. Parsons DW, et al. The genetic landscape of the childhood cancer medulloblastoma. Science. 2011; 331:435–439. [PubMed: 21163964]
7. Yan H, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine. 2009; 360:765–773. [PubMed: 19228619]
8. Brennan CW, et al. The somatic genomic landscape of glioblastoma. Cell. 2013; 155:462–477. [PubMed: 24120142]
9. Schwartzentruber J, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012; 482:226–231. [PubMed: 22286061]
10. Bjerke L, et al. Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer discovery. 2013; 3:512–519. [PubMed: 23539269]
11. Dubuc AM, et al. Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. Acta neuropathologica. 2013; 125:373–384. [PubMed: 23184418]
12. Northcott PA, et al. Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature. 2014; 511:428–434. [PubMed: 25043047]
13. Northcott PA, et al. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nature genetics. 2009; 41:465–472. [PubMed: 19270706]
14. Northcott PA, et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature. 2012; 488:49–56. [PubMed: 22832581]
15. Hovestadt V, et al. Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. Nature. 2014; 510:537–541. [PubMed: 24847876]

16. Jones DT, et al. Dissecting the genomic complexity underlying medulloblastoma. Nature. 2012; 488:100–105. [PubMed: 22832583]
17. Pugh TJ, et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature. 2012; 488:106–110. [PubMed: 22820256]
18. Rausch T, et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell. 2012; 148:59–71. [PubMed: 22265402]
19. Mack SC, et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature. 2014; 506:445–450. [PubMed: 24553142]
20. Lee RS, et al. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. The Journal of clinical investigation. 2012; 122:2983–2988. [PubMed: 22797305]
21. Torchia J, et al. Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. The lancet oncology. 2015; 16:569–582. [PubMed: 25882982]
22. Buczkowicz P, et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nature genetics. 2014; 46:451–456. [PubMed: 24705254]
23. Fontebasso AM, et al. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. 2014; 46:462–466.
24. Malkin H, et al. Nature genetics.
25. Taylor KR, et al. Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nature genetics. 2014; 46:457–461. [PubMed: 24705252]
26. Wu G, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nature genetics. 2012; 44:251–253. [PubMed: 22286216]
27. Wu G, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nature genetics. 2014; 46:444–450. [PubMed: 24705251]
28. Kleinman CL, et al. Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR. Nature genetics. 2014; 46:39–44. [PubMed: 24316981]
29. Calabrese C, et al. A perivascular niche for brain tumor stem cells. Cancer cell. 2007; 11:69–82. [PubMed: 17222791]
30. Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer cell. 2007; 11:335–347. [PubMed: 17418410]
31. Li Z, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer cell. 2009; 15:501–513. [PubMed: 19477429]
32. Fukumura D, et al. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer research. 2001; 61:6020–6024. [PubMed: 11507045]
33. Comerford SA, et al. Acetate dependence of tumors. Cell. 2014; 159:1591–1602. [PubMed: 25525877]
34. Eyler CE, et al. Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell. 2011; 146:53–66. [PubMed: 21729780]
35. Hjelmeland AB, et al. Acidic stress promotes a glioma stem cell phenotype. Cell death and differentiation. 2011; 18:829–840. [PubMed: 21127501]
36. Charles N, et al. Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell stem cell. 2010; 6:141–152. [PubMed: 20144787]
37. Koivunen P, et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature. 2012; 483:484–488. [PubMed: 22343896]
38. Lu C, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012; 483:474–478. [PubMed: 22343901]
39. Turcan S, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012; 483:479–483. [PubMed: 22343889]

40. Slongo ML, et al. Functional VEGF and VEGF receptors are expressed in human medulloblastomas. Neuro-oncology. 2007; 9:384–392. [PubMed: 17704359]
41. Mutoh T, Sanosaka T, Ito K, Nakashima K. Oxygen levels epigenetically regulate fate switching of neural precursor cells via hypoxia-inducible factor 1alpha-notch signal interaction in the developing brain. Stem cells. 2012; 30:561–569. [PubMed: 22213097]
42. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646–674. [PubMed: 21376230]
43. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126:663–676. [PubMed: 16904174]
44. Vierbuchen T, et al. Direct conversion of fibroblasts to functional neurons by defined factors. Nature. 2010; 463:1035–1041. [PubMed: 20107439]
45. Han DW, et al. Direct reprogramming of fibroblasts into neural stem cells by defined factors. Cell stem cell. 2012; 10:465–472. [PubMed: 22445517]
46. Najm FJ, et al. Transcription factor-mediated reprogramming of fibroblasts to expandable, myelinogenic oligodendrocyte progenitor cells. Nature biotechnology. 2013; 31:426–433.
47. Gangemi RM, et al. SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem cells. 2009; 27:40–48. [PubMed: 18948646]
48. Suva ML, et al. Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell. 2014; 157:580–594. [PubMed: 24726434]
49. Sarkar A, Hochedlinger K. The sox family of transcription factors: versatile regulators of stem and progenitor cell fate. Cell stem cell. 2013; 12:15–30. [PubMed: 23290134]
50. Suva ML, Riggi N, Bernstein BE. Epigenetic reprogramming in cancer. Science. 2013; 339:1567–1570. [PubMed: 23539597]
51. Stricker SH, et al. Widespread resetting of DNA methylation in glioblastoma-initiating cells suppresses malignant cellular behavior in a lineage-dependent manner. Genes & development. 2013; 27:654–669. [PubMed: 23512659]
52. Friedmann-Morvinski D, et al. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science. 2012; 338:1080–1084. [PubMed: 23087000]
53. Patel AP, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014; 344:1396–1401. [PubMed: 24925914]
54. Meyer M, et al. Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity. Proceedings of the National Academy of Sciences of the United States of America. 2015; 112:851–856. [PubMed: 25561528]
55. Polak P, et al. Cell-of-origin chromatin organization shapes the mutational landscape of cancer. Nature. 2015; 518:360–364. [PubMed: 25693567]
56. Schuster-Bockler B, Lehner B. Chromatin organization is a major influence on regional mutation rates in human cancer cells. Nature. 2012; 488:504–507. [PubMed: 22820252]
57. Liu L, De S, Michor F. DNA replication timing and higher-order nuclear organization determine single-nucleotide substitution patterns in cancer genomes. Nature communications. 2013; 4:1502.
58. Black JC, et al. KDM4A lysine demethylase induces site-specific copy gain and rereplication of regions amplified in tumors. Cell. 2013; 154:541–555. [PubMed: 23871696]
59. Ben-Porath I, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nature genetics. 2008; 40:499–507. [PubMed: 18443585]
60. Easwaran H, et al. A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome research. 2012; 22:837–849. [PubMed: 22391556]
61. Kim J, et al. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell. 2010; 143:313–324. [PubMed: 20946988]
62. Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC, Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111:2548–2553. [PubMed: 24550281]
63. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012; 489:57–74. [PubMed: 22955616]

64. Kundaje A, et al. Integrative analysis of 111 reference human epigenomes. Nature. 2015; 518:317–330. [PubMed: 25693563]
65. Tessarz P, Kouzarides T. Histone core modifications regulating nucleosome structure and dynamics. Nature reviews Molecular cell biology. 2014; 15:703–708. [PubMed: 25315270]
66. Hodis E, et al. A landscape of driver mutations in melanoma. Cell. 2012; 150:251–263. [PubMed: 22817889]
67. Imielinski M, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012; 150:1107–1120. [PubMed: 22980975]
68. Pugh TJ, et al. The genetic landscape of high-risk neuroblastoma. Nature genetics. 2013; 45:279–284. [PubMed: 23334666]
69. Robinson G, et al. Novel mutations target distinct subgroups of medulloblastoma. Nature. 2012; 488:43–48. [PubMed: 22722829]
70. Zhang J, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature. 2012; 481:329–334. [PubMed: 22237022]
71. Zhang J, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012; 481:157–163. [PubMed: 22237106]
72. Hasselblatt M, et al. High-resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumors. Genes, chromosomes & cancer. 2013; 52:185–190. [PubMed: 23074045]
73. Ho L, et al. An embryonic stem cell chromatin remodeling complex, esBAF, is an essential component of the core pluripotency transcriptional network. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106:5187–5191. [PubMed: 19279218]
74. Roberts CW, Galusha SA, McMenamin ME, Fletcher CD, Orkin SH. Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice. Proceedings of the National Academy of Sciences of the United States of America. 2000; 97:13796–13800. [PubMed: 11095756]
75. Klochendler-Yeivin A, et al. The murine SNF5/INI1 chromatin remodeling factor is essential for embryonic development and tumor suppression. EMBO reports. 2000; 1:500–506. [PubMed: 11263494]
76. Guidi CJ, et al. Disruption of Ini1 leads to peri-implantation lethality and tumorigenesis in mice. Molecular and cellular biology. 2001; 21:3598–3603. [PubMed: 11313485]
77. Roberts CW, Leroux MM, Fleming MD, Orkin SH. Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5. Cancer cell. 2002; 2:415–425. [PubMed: 12450796]
78. Eroglu E, et al. SWI/SNF complex prevents lineage reversion and induces temporal patterning in neural stem cells. Cell. 2014; 156:1259–1273. [PubMed: 24630726]
79. Parker M, et al. C11orf95-RELA fusions drive oncogenic NF-kappaB signalling in ependymoma. Nature. 2014; 506:451–455. [PubMed: 24553141]
80. Johnson RA, et al. Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature. 2010; 466:632–636. [PubMed: 20639864]
81. Witt H, et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer cell. 2011; 20:143–157. [PubMed: 21840481]
82. Li M, et al. Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer cell. 2009; 16:533–546. [PubMed: 19962671]
83. Sin-Chan P, Huang A. DNMTs as potential therapeutic targets in high-risk pediatric embryonal brain tumors. Expert opinion on therapeutic targets. 2014; 18:1103–1107. [PubMed: 25142793]
84. Khuong-Quang DA, et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta neuropathologica. 2012; 124:439–447. [PubMed: 22661320]
85. Bender S, et al. Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer cell. 2013; 24:660–672. [PubMed: 24183680]

86. Chan KM, et al. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes & development. 2013; 27:985–990. [PubMed: 23603901]
87. Sturm D, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer cell. 2012; 22:425–437. [PubMed: 23079654]
88. Lewis PW, et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science. 2013; 340:857–861. [PubMed: 23539183]
89. Funato K, Major T, Lewis PW, Allis CD, Tabar V. Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation. Science. 2014; 346:1529–1533. [PubMed: 25525250]
90. Heaphy CM, et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science. 2011; 333:425. [PubMed: 21719641]
91. Fontebasso AM, et al. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. Acta neuropathologica. 2013; 125:659–669. [PubMed: 23417712]
92. Hnisz D, et al. Super-enhancers in the control of cell identity and disease. Cell. 2013; 155:934–947. [PubMed: 24119843]
93. Mansour MR, et al. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science. 2014; 346:1373–1377. [PubMed: 25394790]
94. Killela PJ, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110:6021–6026. [PubMed: 23530248]
95. Remke M, et al. TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta neuropathologica. 2013; 126:917–929. [PubMed: 24174164]
96. Bell RJ, et al. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science. 2015
97. Zardo G, et al. Integrated genomic and epigenomic analyses pinpoint biallelic gene inactivation in tumors. Nature genetics. 2002; 32:453–458. [PubMed: 12355068]
98. Noushmehr H, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer cell. 2010; 17:510–522. [PubMed: 20399149]
99. Rideout WM 3rd, Coetzee GA, Olumi AF, Jones PA. 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science. 1990; 249:1288–1290. [PubMed: 1697983]
100. Tubio JM, et al. Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. Science. 2014; 345:1251343. [PubMed: 25082706]
101. Venkatesh HS, et al. Neuronal Activity Promotes Glioma Growth through Neuroligin-3 Secretion. Cell. 2015; 161:803–816. [PubMed: 25913192]
102. Young RA. Control of the embryonic stem cell state. Cell. 2011; 144:940–954. [PubMed: 21414485]
103. Mohyeldin A, Garzon-Muvdi T, Quinones-Hinojosa A. Oxygen in stem cell biology: a critical component of the stem cell niche. Cell stem cell. 2010; 7:150–161. [PubMed: 20682444]
104. Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nature reviews Cancer. 2012; 12:9–22.
105. Seidel S, et al. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain : a journal of neurology. 2010; 133:983–995. [PubMed: 20375133]
106. Soeda A, et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene. 2009; 28:3949–3959. [PubMed: 19718046]
107. Wang J, et al. c-Myc is required for maintenance of glioma cancer stem cells. PloS one. 2008; 3:e3769. [PubMed: 19020659]
108. Heddleston JM, et al. Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential. Cell death and differentiation. 2012; 19:428–439. [PubMed: 21836617]
109. Lu Y, Chu A, Turker MS, Glazer PM. Hypoxia-induced epigenetic regulation and silencing of the BRCA1 promoter. Molecular and cellular biology. 2011; 31:3339–3350. [PubMed: 21670155]
110. Shahrzad S, Bertrand K, Minhas K, Coomber BL. Induction of DNA hypomethylation by tumor hypoxia. Epigenetics. 2007; 2:119–125. [PubMed: 17965619]

111. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nature reviews Cancer. 2004; 4:891–899. [PubMed: 15516961]
112. Chiche J, Brahimi-Horn MC, Pouyssegur J. Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. Journal of cellular and molecular medicine. 2010; 14:771–794. [PubMed: 20015196]
113. McBrian MA, et al. Histone acetylation regulates intracellular pH. Molecular cell. 2013; 49:310–321. [PubMed: 23201122]
114. Bao S, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer research. 2006; 66:7843–7848. [PubMed: 16912155]
115. Christensen K, Schroder HD, Kristensen BW. CD133+ niches and single cells in glioblastoma have different phenotypes. Journal of neuro-oncology. 2011; 104:129–143. [PubMed: 21184132]
116. Hambardzumyan D, et al. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes & development. 2008; 22:436–448. [PubMed: 18281460]
117. Bao S, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444:756–760. [PubMed: 17051156]
118. Pietras A, et al. Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. Cell stem cell. 2014; 14:357–369. [PubMed: 24607407]
119. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006; 124:263–266. [PubMed: 16439202]
120. Pyonteck SM, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nature medicine. 2013; 19:1264–1272.
121. Zhou W, et al. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nature cell biology. 2015; 17:170–182. [PubMed: 25580734]
122. Bhat KP, et al. Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma. Cancer cell. 2013; 24:331–346. [PubMed: 23993863]
123. Ortiz B, et al. Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111:8149–8154. [PubMed: 24843164]
124. Zhu TS, et al. Endothelial cells create a stem cell niche in glioblastoma by providing NOTCH ligands that nurture self-renewal of cancer stem-like cells. Cancer research. 2011; 71:6061–6072. [PubMed: 21788346]
125. Lobov IB, et al. Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104:3219–3224. [PubMed: 17296940]
126. Giancotti FG. Mechanisms governing metastatic dormancy and reactivation. Cell. 2013; 155:750–764. [PubMed: 24209616]
127. Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nature medicine. 1996; 2:209–215.
128. Ghajar CM, et al. The perivascular niche regulates breast tumour dormancy. Nature cell biology. 2013; 15:807–817. [PubMed: 23728425]
129. Magnus N, et al. Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111:3544–3549. [PubMed: 24520174]
130. Lee JV, et al. Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation. Cell metabolism. 2014; 20:306–319. [PubMed: 24998913]
131. Wellen KE, et al. ATP-citrate lyase links cellular metabolism to histone acetylation. Science. 2009; 324:1076–1080. [PubMed: 19461003]
132. Mashimo T, et al. Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell. 2014; 159:1603–1614. [PubMed: 25525878]

133. Wise DR, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105:18782–18787. [PubMed: 19033189]

134. Cascon A, et al. Whole-exome sequencing identifies MDH2 as a new familial paraganglioma gene. Journal of the National Cancer Institute. 2015; 107

135. Hao HX, et al. SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science. 2009; 325:1139–1142. [PubMed: 19628817]

136. Rohle D, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013; 340:626–630. [PubMed: 23558169]

137. Flavahan WA, et al. Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nature neuroscience. 2013; 16:1373–1382. [PubMed: 23995067]

138. Korkola JE, et al. Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. Cancer research. 2006; 66:820–827. [PubMed: 16424014]

139. Levasseur DN, Wang J, Dorschner MO, Stamatoyannopoulos JA, Orkin SH. Oct4 dependence of chromatin structure within the extended Nanog locus in ES cells. Genes & development. 2008; 22:575–580. [PubMed: 18283123]

140. Kaelin WG Jr, McKnight SL. Influence of metabolism on epigenetics and disease. Cell. 2013; 153:56–69. [PubMed: 23540690]

141. Ecke I, et al. Antitumor effects of a combined 5-aza-2'deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice. Cancer research. 2009; 69:887–895. [PubMed: 19155313]

142. Milde T, et al. HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment. Journal of neuro-oncology. 2012; 110:335–348. [PubMed: 23054560]

143. Spiller SE, Ditzler SH, Pullar BJ, Olson JM. Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA). Journal of neuro-oncology. 2008; 87:133–141. [PubMed: 18060600]

144. Pal R, et al. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nature medicine. 2014; 20:1394–1396.

145. Grasso CS, et al. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. 2015

146. Alimova I, et al. Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells. Neuro-oncology. 2013; 15:149–160. [PubMed: 23190500]

147. Kim E, et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer cell. 2013; 23:839–852. [PubMed: 23684459]

148. Filippakopoulos P, et al. Selective inhibition of BET bromodomains. Nature. 2010; 468:1067–1073. [PubMed: 20871596]

149. Henssen A, et al. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. Oncotarget. 2013; 4:2080–2095. [PubMed: 24231268]

150. Link BA, et al. Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Nature medicine. 2014; 5:2355–2371.



Figure 1. The Epigenetic Gateway to Cell Identity and Neoplastic Transformation

A schematic depicting the genetic, metabolic, and microenvironmental interactions (green arrows) with epigenetic programs in cancer (top panel). In the lower panel, a diagram illustrating the cell state transitions (red arrows) influenced by altered epigenetic landscapes and their relevance to both normal neural stem cell, and cancer stem cell hierarchies (lower panel). Within the cells are green pie-shaped triangles, which represent the restructuring of chromatin architecture and progression towards closed chromatin in the most differentiated cell state.



Figure 2. Brain Tumors Converge on Chromatin Architecture

A diagram depicting euchromatin and histone modifications that mediate ‘active’ transcription in cancer cells (top panel). Shown are various histone modifications and enzymes, which catalyze the addition of post-translational modifications such as histone methylation and acetylation, or bind to these modifications, such as the BRD4, which binds acetylated lysine residues on histones. The green ovals represent transcription factor binding sites and locations of enhancers, or clusters of enhancers, termed super-enhancers. Also shown are drug compounds, which inhibit the removal (Vorinostat and Pabinostat - Histone deacetylase (HDAC) inhibitor) or detection of acetylation (JQ1). Shown in the middle are the chromatin remodelers, which facilitate the landscape of higher order chromatin structure towards euchromatin or heterochromatin. In the lower panel, heterochromatin is depicted and the associated modifications that mediate tumor suppressor gene silencing. These

include the DNA methyltransferase family of enzymes, which catalyze the addition of methyl groups to cytosine - guanine di-nuclueotides, and TET enzymes, which facilitate DNA de-methylation through 5-methyl cytosine hydroxylation. Also shown is EZH2, which methylates at histone H3 at the 27th position, and the associated histone H3K27 de-methylases KDM6A and JMJD3. Shown are chemical inhibitors that reverse the methylation marks deposited or removed by these methyltransferase and demethylase enzymes related to heterochromatin (Decitabine, GSK343, GSKJ4). ATRX and DAXX are depicted which function to incorporate the histone H3.3 variant, and which are frequently mutated in pediatric high-grade glioma.



Figure 3. Cellular Microenvironment Influences Epigenetic State of Brain Tumor Cells

An illustration of the brain tumor microenvironment highlighting the perivascular and hypoxic niches, which dictate interacting cell types and nutrient availabilities. Both cancer cells (light green) and brain tumor cells (purple-round) exist in dynamic microenvironments containing exogenous signals from surrounding microglia (purple), pericytes (dark pink), endothelial cells (light pink), and other neoplastic cells. These interactions occur in the presence of variable growth factor gradients (ie. VEGF), oxygen availability, and nutrient levels (i.e. glucose, acetate, glutamine etc.).



Figure 4. Cellular Metabolism Influences Brain Cancer Epigenetic State

A schematic of metabolic pathways present within a bran tumor cell with emphasis on transport proteins (GLUT3), and enzymatic effectors (IDH1/2 mutations, ACSS2, and ACLY (ATP citrate lyase)), which alter tumor metabolism and ultimately epigenetic programs. The result of the IDH1 mutation is emphasized, which results in the accumulation of 2-hydroxyglutarate, a metabolite that inhibits the function of iron, oxygen, and α-ketoglutarate dependent demethylase enzymes, thus leading to aberrant accumulation of both DNA and histone methylation.